USD
+$0.00
(+0.00%
)At Close (As of Oct 13, 2025)
$1.71B
Market Cap
-
P/E Ratio
-3.57
EPS
$27.20
52 Week High
$9.90
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $302K |
Total Revenue | $302K |
Cost Of Revenue | $1.2M |
Costof Goods And Services Sold | $1.2M |
Operating Income | -$299M |
Selling General And Administrative | $61M |
Research And Development | $238M |
Operating Expenses | $299M |
Investment Income Net | - |
Net Interest Income | $29M |
Interest Income | $32M |
Interest Expense | $3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.2M |
Income Before Tax | -$270M |
Income Tax Expense | -$270M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$270M |
Comprehensive Income Net Of Tax | - |
Ebit | -$267M |
Ebitda | -$266M |
Net Income | -$270M |
Field | Value (USD) |
---|---|
Total Assets | $742M |
Total Current Assets | $738M |
Cash And Cash Equivalents At Carrying Value | $100M |
Cash And Short Term Investments | $100M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $3.9M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $618M |
Other Current Assets | $21M |
Other Non Current Assets | - |
Total Liabilities | $71M |
Total Current Liabilities | $48M |
Current Accounts Payable | $2.1M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $513K |
Total Non Current Liabilities | $23M |
Capital Lease Obligations | $513K |
Long Term Debt | $21M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $21M |
Other Current Liabilities | $45M |
Other Non Current Liabilities | $2M |
Total Shareholder Equity | $672M |
Treasury Stock | - |
Retained Earnings | -$996M |
Common Stock | $810K |
Common Stock Shares Outstanding | $68M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$232M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.2M |
Capital Expenditures | $511K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$229M |
Cashflow From Financing | $458M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$270M |
Field | Value (USD) |
---|---|
Gross Profit | $302K |
Total Revenue | $302K |
Cost Of Revenue | $1.2M |
Costof Goods And Services Sold | $1.2M |
Operating Income | -$299M |
Selling General And Administrative | $61M |
Research And Development | $238M |
Operating Expenses | $299M |
Investment Income Net | - |
Net Interest Income | $29M |
Interest Income | $32M |
Interest Expense | $3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.2M |
Income Before Tax | -$270M |
Income Tax Expense | -$270M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$270M |
Comprehensive Income Net Of Tax | - |
Ebit | -$267M |
Ebitda | -$266M |
Net Income | -$270M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on advancing innovative therapies for patients with severe diseases, particularly in the areas of rare and autoimmune disorders. Headquartered in Boulder, Colorado, the company leverages cutting-edge research and development to create breakthrough treatments that address unmet medical needs. With a robust pipeline of candidates and a commitment to improving patient outcomes, Viridian is well-positioned to make significant contributions to the therapeutic landscape.